Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-25

FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Lupin Pharmaceuticals,Inc.)

View source ↗

Summary

The FDA approved Lupin Pharmaceuticals' supplemental application for dextroamphetamine sulfate, a generic stimulant used to treat attention-deficit/hyperactivit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dextroamphetamine sulfate (dextroamphetamine sulfate)

Snippet

SUPPL AP for DEXTROAMPHETAMINE SULFATE (DEXTROAMPHETAMINE SULFATE)